| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Monopar Therapeutics (MNPR) has 11 insiders with recent SEC Form 4 filings, including 12 buys and 5 sells. MNPR is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 567.6K | $36.08M | - | |
| CEO | 272.0K | $17.29M | - | |
| CEO | 85.7K | $5.45M | - | |
| COO | 48.3K | $3.07M | - | |
| Dir | 9.2K | $586.4K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 4, 2024 | Cittadine Andrew69 | Chief Operating Officer | Buy | 24,000 | $0.77 | $18,480.00 | +12.0% | -38.4% | +825.7% | |
| May 31, 2024 | Cittadine Andrew69 | Chief Operating Officer | Buy | 36,000 | $0.64 | $23,050.80 | +17.2% | -22.4% | +938.5% | |
| Nov 15, 2022 | Cittadine Andrew69 | Chief Operating Officer | Buy | 16,053 | $3.09 | $49,659.00 | +71.6% | +30.2% | -88.1% | |
| Feb 11, 2021 | Tactic Pharma LLC | Chief Scientific Officer | Sell | 125,000 | $14.64 | $1,830,619.84 | -11.0% | - | - | |
| Dec 18, 2019 | Tactic Pharma LLC | Chief Scientific Officer | Buy | 125,000 | $8.00 | $1,000,000.00 | +75.0% | - | - | |
| Dec 18, 2019 | Tsuchimoto Kim R | Chief Financial Officer | Buy | 325 | $8.00 | $2,600.00 | New | - | - | |
| Dec 18, 2019 | Hendricks Diane | 10% Owner | Buy | 468,750 | $8.00 | $3,750,000.00 | New | - | - | |
| Dec 18, 2019 | Leo Karl | 10% Owner | Buy | 156,564 | $8.00 | $1,252,510.00 | New | - | - |